Functional changes in Becker muscular dystrophy: Implications for clinical trials in dystrophinopathies

Luca Bello, Paola Campadello, Andrea Barp, Marina Fanin, Claudio Semplicini, Gianni Sorarù, Luca Caumo, Chiara Calore, Corrado Angelini, Elena Pegoraro

Research output: Contribution to journalArticlepeer-review


We performed a 1-year longitudinal study of Six Minute Walk Test (6MWT), North Star Ambulatory Assessment (NSAA), and timed function tests in Becker muscular dystrophy (BMD). Skeletal muscle dystrophin was quantified by immunoblot. We grouped deletions ending on exon 45 ("del 45-x", n = 28) or 51 ("del x-51", n = 10); isolated exon 48 deletion ("del 48", n = 10); and other mutations (n = 21). Only patients in the "del 45-x" or "other" groups became non-ambulatory (n = 5, log-rank p = n.s.) or unable to run (n = 22, p < 0.001). All measures correlated positively with dystrophin quantity and negatively with age, and were significantly more impaired in the "del 45-x" and "other" groups. After one year, NSAA score decreased significantly (-0.9 ± 1.6, p < 0.001); in the "del 45-x" group, both NSAA (-1.3 ± 1.7, p = 0.001) and 6MWT (-12 ± 31 m, p = 0.059) decreased. We conclude that patients with "del x-51" or "del 48" mutations have mild or asymptomatic BMD, while "del 45-x" mutations cause comparatively severe weakness, and functional deterioration in 1 year. Furthermore, exon 51 skipping could be more effective than exon 45 skipping in Duchenne muscular dystrophy.

Original languageEnglish
Article number32439
JournalScientific Reports
Publication statusPublished - Sep 1 2016

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Functional changes in Becker muscular dystrophy: Implications for clinical trials in dystrophinopathies'. Together they form a unique fingerprint.

Cite this